How the UK is setting new standards for genomic research and better health care
Read how an integrated BaseSpace workflow tracks samples from library prep through data analysis to deliver high-quality sequencing data with full traceability.
Illumina DRAGEN (Dynamic Read Analysis for GENomics) secondary analysis enables labs of all sizes and disciplines to maximize the value of the genome with powerful, cutting-edge data analysis tools. DRAGEN secondary analysis (formerly known as the DRAGEN Bio-IT Platform) provides accurate, comprehensive, and highly efficient bioinformatics with multiple deployment options, applications, and pipelines to meet your research needs.
Confidently analyze with exceptionally accurate results. DRAGEN achieved a 99.90% accuracy1 score using the Precision FDA Truth Challenge v2 benchmark data.
Analyze whole genomes, exomes, methylomes, and transcriptomes with a single solution that replaces up to 30 open-source tools.
Process a 40× genome in ~ 34 min, with all supported callers.2 Reduce FASTQ file sizes up to 5× with DRAGEN ORA compression. DRAGEN secondary analysis resulted in two world speed records for genomic data analysis.3,4
Built-in lossless data compression decreases storage costs by 80%5. Preconfigured workflows reduce time and expense for developing and maintaining analysis pipelines.
Meeting you where your data and expertise is. DRAGEN secondary analysis is available via on-premises server, in the cloud, or directly onboard the NovaSeq X Series, NextSeq 1000 and NextSeq 2000 Systems, and the MiSeq i100 Series.
Easily integrate with Illumina sequencers, enabling a streamlined workflow from sequencing to downstream tertiary analysis.
Access DRAGEN via an on-premises server, cloud-based, or on-instrument solution. Multiple deployment options support your analysis needs without compromising accuracy, speed, or flexibility.
DRAGEN supports an extensive range of applications, providing comprehensive coverage for many experiment types in a single solution. Key applications include:
DRAGEN includes a versatile set of pipelines that can accept input data files and create output files at different stages of the pipelines.
The DRAGEN Iterative gVCF Genotyper (IGG) delivers a breakthrough solution for population-scale variant analysis, enabling fast, efficient aggregation and genotyping of small germline variants across large cohorts. Designed for speed, accuracy, and scalability, IGG supports incremental analysis so new sample batches can be added without reprocessing the entire dataset.
In our hands, using DRAGEN [secondary] analysis, we have realized cost savings of approximately 50%. In terms of computational time, it’s almost double the speed compared to the manual method.
From genetic diseases to oncology to pharmacogenomics and more, DRAGEN can help labs in any field scale up NGS operations and make game-changing genomic analysis a reality.
How the UK is setting new standards for genomic research and better health care
Read how an integrated BaseSpace workflow tracks samples from library prep through data analysis to deliver high-quality sequencing data with full traceability.
Can genomics stop the world’s leading cause of death?
DRAGEN helps Cardio-CARE cut their data-processing time, reduce their data storage footprint by 80%, and rapidly analyze WGS data for a study with 9000+ participants.
A starring role for pharmacogenomics: “star allele” calling for critical PGx genes
The DRAGEN PGx pipeline enables genotyping of 20 genes related to drug metabolism to support new drug development.
The evolution of the multigenome mapping methodology using pangenome references, showing significant accuracy improvements.
Discover how DRAGEN somatic indel methods enabled high accuracy variant calling in the NCTR indel calling from Oncopanel Sequencing Data Challenge.
Discover how multi-region joint detection (MRJD) addresses the challenge of de novo germline variant calling in difficult to map regions of the genome.
Watch this on-demand webinar to learn about cancer research applications for heme WGS, solid WGS tumor-normal, and a streamlined pipeline for minimal residual disease (MRD) with improvements in germline and somatic pipelines, as well as structural variant calling.
Try DRAGEN with a free trial with no credit card required. Run real analyses on your own data.
References